Here's why the Imugene (ASX:IMU) share price is having such a stellar day

A cancer trial update appears to be exciting investors on Wednesday.

Key points
  • The Imugene share price is in the green today 
  • The biotech company's shares have shot up 137% in a year 
  • Imugene has received ethics approval for a trial of a new cancer virotherapy 

The Imugene Ltd (ASX: IMU) share price is climbing today on the back of a clinical update from the biotech company.

Imugene shares are currently trading at 28 cents, a 7.69% gain. In contrast, the  S&P/ASX 200 Index (ASX: XJO) is up 0.53% at the time of writing.

Let's take a look at what Imugene announced today.

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

Clinical trial update

Imugene has received Western Institutional Review Board approval to kickstart a phase one clinical trial of a new cancer treatment.

The company will look into the use of its oncolytic virotherapy candidate, known as Vaxinia, on multiple solid tumours.

The world-renowned City of Hope cancer treatment centre near Los Angeles is the first hospital in the US to receive ethics approval. Further clinical sites will open in the US in 2022. Patient recruitment will start immediately.

Commenting on the start of the trial, CEO and managing director Leslie Chong said:

Accomplishing this goal speaks to the perseverance and dedication of Imugene's clinical and research team as we continue to build on our clinical and commercial potential.

Following the outstanding work of Professor Yuman Fong and the City of Hope team, in addition to the positive pre-clinical results, we're incredibly eager to unlock the potential of VAXINIA and the oncolytic virotherapy platform more broadly.

The trial will be conducted via the Food and Drug Administration investigational new drug process. Imugene received US Food and Drug Administration (FDA) approval for the trial in December.

Share price snapshot

The Imugene share price has skyrocketed 137% in the past year. However, it has dropped around 29% year to date.

In contrast, the broader ASX 200 Index has returned about 9% in the past 52 weeks.

During the past month, Imugene shares have gained nearly 12%, up more than 16% in the past week.

Imugene has a market capitalisation of about $1.6 billion based on its current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »